Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Thrombocytopenia 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Colorectal Neoplasms 1Chemotherapy-induced Thrombocytopenia 1CTIT: Cancer Therapy Induced Thrombocytopenia 1

Interventions

Cyclophosphamide 50fludarabine phosphate 47Busulfan 46Cyclosporine 36Antilymphocyte Serum 33Cytarabine 32Peripheral Blood Stem Cell Transplantation 30Radiotherapy 28Filgrastim 27Methotrexate 23Melphalan 23Mycophenolic Acid 21Cord Blood Stem Cell Transplantation 21Methylprednisolone 20Etoposide 17Whole-Body Irradiation 16Tacrolimus 15Daunorubicin 11Epoetin Alfa 10fludarabine 9Thiotepa 9Alemtuzumab 8Idarubicin 7Granulocyte Colony-Stimulating Factor 7sargramostim 6Topotecan 6Mitoxantrone 6Azacitidine 6Arsenic Trioxide 6Gemtuzumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × oprelvekin × Classical hematology × Clear all
NCT00493181 2012-02-20

Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients

M.D. Anderson Cancer Center

Phase 2 Completed
8 enrolled 3 charts
Classical hematologyMyeloidOther hematologic neoplasm

Leukemia, Thrombocytopenia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡